Last reviewed · How we verify

Carogra (Carotegrast methyl)

EA Pharma Co., Ltd. · FDA-approved active Small molecule ✓ Verified May 2026 Quality 17/100

Carogra (generic name: Carotegrast methyl) is a Small molecule drug developed by EA Pharma Co., Ltd.. It is currently FDA-approved for Ulcerative colitis.

Carotegrast methyl is a medication used to treat ulcerative colitis. Its mechanism of action is not specified in the provided information.

At a glance

Generic nameCarotegrast methyl
SponsorEA Pharma Co., Ltd.
TargetIntegrin alpha-4/beta-1
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Carogra

What is Carogra?

Carogra (Carotegrast methyl) is a Small molecule drug developed by EA Pharma Co., Ltd., indicated for Ulcerative colitis.

What is Carogra used for?

Carogra is indicated for Ulcerative colitis.

Who makes Carogra?

Carogra is developed and marketed by EA Pharma Co., Ltd. (see full EA Pharma Co., Ltd. pipeline at /company/ea-pharma-co-ltd).

What is the generic name of Carogra?

Carotegrast methyl is the generic (nonproprietary) name of Carogra.

What development phase is Carogra in?

Carogra is FDA-approved (marketed).

What does Carogra target?

Carogra targets Integrin alpha-4/beta-1.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing